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A
P-2 transcription factors have been implicated 
in epidermal biology, but their functional signiﬁ  -
cance has remained elusive. Using conditional 
knockout technology, we show that AP-2α is essential for 
governing the balance between growth and differentiation 
in epidermis. In vivo, epidermis lacking AP-2α exhibits 
elevated expression of the epidermal growth factor recep-
tor (EGFR) in the differentiating layers, resulting in hyper-
proliferation when the receptors are activated. Chromatin 
immunoprecipitation and promoter activity   assays identify 
EGFR as a direct target gene for AP-2α   repression, and, 
in the absence of AP-2α, this is manifested primarily in 
excessive EGF-dependent phosphoinositol-3 kinase/Akt 
activity. Together, our ﬁ  ndings unveil a hitherto unrecog-
nized repressive role for AP-2α in governing EGFR gene 
transcription as cells exit the basal layer and withdraw 
from the cell cycle. These results provide insights into why 
elevated AP-2α levels are often associated with terminal 
differentiation and why tumor cells often display reduced 
AP-2α and elevated EGFR proteins.
Introduction
Mammalian skin epithelium is a self-renewing tissue that consti-
tutes the barrier between an organism and its environment. 
To provide the organism with this essential function, epidermis 
must balance proliferation and differentiation (Niemann and 
Watt, 2002; Dai and Segre, 2004). Its innermost basal layer ad-
heres to an underlying basement membrane rich in ECM. This 
layer contains proliferative keratinocytes that are typifi  ed by 
their expression of genes encoding integrins and growth factor 
receptors, particularly EGF receptor (EGFR; also referred to as 
ErbB1), as well as the structural keratins 5 and 14 (K5 and K14; 
Fuchs and Raghavan, 2002; Atit et al., 2003). As basal cells 
move upward, they repress basally expressed genes and switch 
to expressing a set of differentiation-associated proteins, includ-
ing keratins K1 and K10. As keratinocytes continue their trek, 
they further adjust their transcriptional program to culminate in 
the production of dead, fl  attened squames that are sloughed from 
the skin surface as new cells moving outward replace them.
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Epidermal homeostasis is under tight transcriptional regu-
lation (Dai and Segre, 2004). Sequence motifs for the binding of 
the AP-2 family of transcription factors are found in most epi-
dermal promoters and enhancers irrespective of terminal differ-
entiation status (Leask et al., 1990; Byrne et al., 1994; Wang 
et al., 1997; Zeng et al., 1997; Maytin et al., 1999; Sinha et al., 
2000; Kaufman et al., 2002; Luo et al., 2002; Vernimmen et al., 
2003). Of the fi  ve known murine AP-2 proteins, four are differ-
entially expressed in the skin. Of these, AP-2α is most highly 
expressed (Byrne et al., 1994; Panteleyev et al., 2003), making 
it an attractive candidate transcription factor for regulating 
 epidermal-specifi  c transcription.
Although a role for AP-2 factors in epidermal gene ex-
pression seems likely, a clear picture as to how they may be in-
volved has not yet emerged. Do AP-2 family members promote 
or repress proliferation and/or differentiation? Are these effects 
dependent on the particular AP-2 family member expressed or 
the relative differentiation stage of the keratinocytes? Often, 
studies have led to seemingly opposing conclusions. In cultured 
keratinocytes, for example, AP-2α seems to repress the pro-
moter activity of the basal cell keratin gene K5 (Byrne et al., 
1994), but in vivo, AP-2 factors are expressed throughout the 
epidermis and K5 is restricted to basal cells. In hyperprolifera-
tive skin, AP-2 factors are coexpressed with K5 suprabasally 
(Panteleyev et al., 2003).T
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Data on the role of AP-2 proteins in other epithelial cells 
offer little assistance in resolving these issues, where both  active 
and repressive roles for AP-2 proteins have been described 
(Johnson, 1996; Maytin et al., 1999; Braganca et al., 2003). 
In mammary carcinoma cell lines, for instance, 5′ regulatory 
sequences for the growth-promoting TGFα and the ErbB 
subfamily of EGFR genes seem to be positively regulated by 
AP-2α (Wang et al., 1997), whereas overexpression of AP-2α 
appears to be growth and proliferation inhibitory (Zhang et al., 
2003). Similarly, in breast cancer tissue, enhanced expression 
of ErbB2 is a frequent occurrence, and yet diminished AP-2α 
expression has often been cited as a poor prognostic marker for 
breast cancer survival (Pellikainen et al., 2004; Friedrichs et al., 
2005). These tantalizing but often contrasting results underscore 
the importance of resolving the possible link between AP-2α 
and epithelial growth.
A major diffi  culty in evaluating how AP-2 family mem-
bers orchestrate transcriptional regulation in skin epidermis 
stems from the disparate results obtained from functional stud-
ies across different vertebrate species. In frog embryos, injec-
tion of antisense AP-2α oligonucleotides leads to the loss of 
epidermal character and the gain of neural gene expression (Luo 
et al., 2002). In contrast, the embryonic epidermis of mice lack-
ing AP-2α seems to develop normally, although early perinatal 
lethality has precluded analyses of postnatal mouse skin 
(Schorle et al., 1996; Zhang et al., 1996; Talbot et al., 1999). 
The physiological relevance of other AP-2 family members in 
skin also remains unknown, as AP-2β–null mice do not display 
a skin phenotype, and targeting of AP-2γ results in lethality 
  before epidermal and follicle development (Hilger-Eversheim 
et al., 2000; Auman et al., 2002).
In this study, we use conditional gene targeting of AP-2α 
to explore the functional signifi  cance of AP-2α in postnatal skin 
development. We show that AP-2α functions in the epidermis 
by repressing EGFR gene expression as cells exit the basal layer 
and commit to terminally differentiate. We show that nuclear 
AP-2α is present normally in some basal and many suprabasal 
epidermal cells and that it is essential for governing the EGFR-
mediated control of epidermal cell proliferation. Other AP-2 
family members do not appear to compensate in the suprabasal 
differentiating epidermal layers, where EGFR expression fails 
to switch off in the absence of AP-2α. Upon growth factor sig-
naling and EGFR activation, AP-2α–null epidermis displays 
hyperproliferation and formation of papilloma-like invagina-
tions accompanied by abnormal suprabasal elevation of acti-
vated Akt. Finally, we show that, mechanistically, the EGFR 
promoter possesses AP-2–binding sites that are occupied by 
AP-2α and that transcriptionally temper receptor gene 
  expression. In vitro, loss of AP-2α elevates EGFR gene tran-
scription, and regulatory circuitries for the phosphoinositol-3 
kinase (PI3K), Akt, and MAPK fail to function properly. These 
fi  ndings have major implications for understanding why reduc-
tions in AP-2 expression have been associated with tumorigene-
sis and cancer.
Figure 1.  Targeted ablation of AP-2𝗂 gene expression in mouse epidermis. K14-Cre:AP-2α
lox/lox conditional knockout (cKO) mice were generated and 
compared with their control wild-type (WT) littermates. (A) PCR genotype analysis. Bands were of the expected sizes. (B) Real-time PCR on P0 epidermal 
mRNAs. Primers are speciﬁ  c for the ﬁ  ve known AP-2 family members. Error bars represent SD. (C) Immunoblot analyses of P0 epidermal extracts probed 
with antibodies to AP-2α and AP-2γ, the two most abundantly expressed members. (D) Immunoﬂ  uorescence microscopy. Color coding is for secondary 
  antibodies used in detection. Nuclei are counterstained with DAPI. Note that in WT skin, the basal epidermal layer displayed some cells with strong 
anti–AP-2α labeling (white arrows) and others with weaker labeling (yellow arrows). In the inner spinous layers, cells were typically strongly labeled.   
Anti-AP2α labeling was uniformly absent in cKO skin. De, dermis; epi, epidermis; hf, hair follicle. Dotted white lines denote dermo–epidermal boundaries. 
Solid white lines denote skin surface. Bars, 20 μm.T
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Results
Conditional ablation of the AP-2𝗂 gene 
in mouse skin epidermis
Recently, mice were genetically engineered so that essential 
coding sequences of the AP-2α gene were fl  anked by loxP sites 
(AP-2α
lox/lox; Brewer et al., 2004). To elucidate the role of 
AP-2α in postnatal skin epidermis, we bred these animals to 
mice harboring a K14-Cre recombinase transgene, which 
 effi  ciently expresses Cre throughout epidermis by embryonic 
day  (E) 15.5 (Vasioukhin et al., 1999). The heterozygous 
K14-Cre:AP-2α
lox/+ line was phenotypically indistinguishable 
from wild type (WT). Offspring generated from matings of 
K14-Cre:AP-2α
lox/+ lines were produced at expected Mende-
lian ratios of genotypes according to PCR analyses of genomic 
DNA (Fig. 1 A).
Expression of other AP-2 family members 
in epidermis is not affected by loss 
of AP-2𝗂
Microarray analyses revealed the presence of AP-2α, AP-2ε, 
and AP-2γ mRNAs in E18.5 skin epidermis, whereas AP-2δ is 
primarily in dermis (unpublished data; for expression analyses, 
see Williams et al., 1988; Byrne et al., 1994; Panteleyev et al., 
2003). We corroborated and extended these results by conduct-
ing real-time PCR on mRNAs isolated from WT epidermis that 
was purifi  ed from skin by dispase treatment. Expression of 
AP-2α and AP-2γ mRNAs was particularly high (Fig. 1 B). 
Similar analyses on K14-Cre:AP-2α
lox/lox showed that the signal 
for AP-2α’s Mfl  oxed coding exon was abolished, verifying the 
effi   cacy of the targeting event. Importantly, the absence of 
AP-2α did not appreciably affect the expression of any of the 
other AP-2 family members, indicating a failure to compensate 
at the level of gene expression (Fig. 1 B).
Immunoblot analyses confi  rmed the expression of AP-2α 
and AP-2γ in WT skin epidermis and verifi  ed that the AP-2α 
targeting event resulted in the loss of AP-2α protein production 
and also underscored the specifi  city of the AP-2α antibody (Fig. 
1 C). By immunofl  uorescence, anti-AP2α labeled basal and su-
prabasal nuclei of WT cells, whereas anti-AP2γ preferentially 
labeled basal nuclei (Fig. 1 D and not depicted). Consistent with 
our protein studies, anti-AP2α staining was absent in K14-Cre:
AP-2α
lox/lox skin, and anti-AP2γ staining was unchanged. Here-
after, we refer to the K14-Cre:AP-2α
lox/lox mice as conditional 
knockout (KO [cKO]).
Morphological changes associated with 
conditional ablation of AP-2𝗂 in epidermis
In agreement with and expected from previous reports of the full 
KO of AP-2α in mice, the skin surface of newborn cKO pups ap-
peared similar to that of their WT littermates (not depicted; Schorle 
et al., 1996; Zhang et al., 1996; Talbot et al., 1999). Upon histologi-
cal inspection, however, cKO skin displayed a thickened interfol-
licular epidermis (Fig. 2 A). Despite the complete absence of 
AP-2α, the thickening was not uniform across the postnatal day 
(P) 0–3 epidermis and began to wane altogether by P6. These aber-
rations had not been noted previously in the straight AP-2α KO an-
imals that died at birth. Whether this is attributable to the relatively 
mild nature of the defects or to strain-related differences in the mice 
used for the two studies (Talbot et al., 1999) was not addressed.
Figure 2.  Analysis of morphological and phenotypic defects in AP-2𝗂 cKO mice. (A) 0.75-μm semi-thin sections stained with toluidine blue showing epi-
dermal morphology beginning at postnatal day 1 (P1)–P3. Vertical bars represent the thickness of the epidermis. (B and C) Thoracic hair loss is associated 
with papilloma-like invaginations and hyperthickened epidermis in adult ( 6 mo old) conditionally AP-2α–null mice. (D) Thickened dorsal ear skin in condi-
tionally AP-2α–null adult mice. Inset shows a high magniﬁ  cation of the dorsal ear skin in conditionally AP-2α–null adult mice, with an arrow denoting the 
site of parakeratosis. C and D are H&E-stained sections (8 μM). Dotted lines denote dermo–epidermal boundaries. Hf, hair follicle.JCB • VOLUME 172 • NUMBER 3 • 2006  412
Figure 3.  Enhanced proliferation in AP-2𝗂–null cKO skin. (A and B) Immuno-
ﬂ  uorescence (A) and in situ hybridizations (B) of 8-μm frozen sections from 
neonatal skins labeled with the antibodies or probes indicated. Color cod-
ing is according to the secondary antibodies used; some images are 
  counterstained with DAPI (blue). Insets in B show double indirect immuno-
ﬂ  uorescence analysis of the expression of K5 protein marking the basal 
layer (red) and K1 marking spinous layers (green). Arrows denote supra-
basal K5 expression in the hyperproliferative region. (C) Neonatal mice 
were injected subcutaneously with BrdU at 50 μg/g wt, and pups were 
killed 4 h later and processed for immunohistochemical localization of 
BrdU in tissue sections. Shown are representative images and quantiﬁ  ca-
tion of BrdU labeling data. Data were collected from two independently 
  labeled sets of animals, and basal epidermal cells were scored for strong 
BrdU incorporation. Results are shown as percent BrdU-labeled cells of the 
total basal layer cells counted (WT, n = 1,572; KO, n = 1,700). Asterisk 
denotes signiﬁ  cant difference from WT cells (P < 0.001) by t test. Error 
bars represent SD. (D) Thoracic skins of adult mice were processed for 
  immunoﬂ  uorescence microscopy as in A. (top) Arrows denote Ki67-positive 
cells in suprabasal layers of cKO epidermis. (bottom) Arrows denote the 
sole active caspase 3 (Cas3)–positive cells, located in hair follicles (hf) that 
are known to undergo apoptosis at the end of each hair cycle. Dotted lines 
denote dermo–epidermal borders. Bars, 20 μm.
Our conditional targeting strategy enabled us to exam-
ine, for the fi  rst time, the consequences of AP-2α loss to post-
natal skin development. As the animals aged, AP-2α cKO 
adult mice progressively lost their hair in select regions of 
their coats. The loss of hair was most pronounced on the ven-
tral thoracic surface, where a large area of skin always became 
bald (Fig. 2 B). Histological analyses revealed that in contrast 
to the typically thin epidermis of adult WT animals, the AP-2α 
cKO animals displayed hyperthickened, papilloma-like undu-
lations throughout these expansive areas (Fig. 2 C). As judged 
by light and electron microscopy, these undulations displayed 
epidermal rather than hair follicle morphology. In addition to 
thoracic skin epithelium, dorsal ear epidermis was also mark-
edly affected, typifi  ed by both hyperthickening and parakera-
tosis in cKO skin (Fig. 2 D).
Classical signs of a hyperproliferative skin 
disorder in AP-2𝗂 cKO mice
To examine the consequences of AP-2α ablation on epidermal 
differentiation, we fi  rst used immunofl  uorescence microscopy 
(Fig. 3). In regions where the AP-2α–null epidermis appeared 
morphologically normal, differentiation markers were  expressed 
in patterns indistinguishable from WT skin. These included 
basal keratins K5 and K14, the spinous layer keratins K1 and 
K10, and granular layer proteins fi  laggrin and loricrin (Fig. 3 A 
and not depicted; for review see Fuchs and Raghavan, 2002). 
In hyperthickened regions, the classical changes in gene 
  expression associated with the hyperproliferative state were 
observed (Weiss et al., 1984), including sustained 
  expression of keratins K5 and K14 in the suprabasal layers and 
induction of the outer root sheath keratins K6, K16, and K17 
in the suprabasal layers of the epidermis (Fig. 3, A and B; and 
not depicted). These abnormalities were accompanied by an 
approximately two- to threefold increase in proliferation in the 
basal layer as judged by BrdU incorporation (Fig. 3 C) and by 
labeling with antibodies against the proliferating nuclear 
  antigen Ki67 (not depicted).
The biochemical abnormalities noted in hyperthickened 
neonatal regions were enhanced in the adult papilloma-like in-
vaginations (Fig. 3 D). In addition, the papilloma-like regions 
displayed some suprabasal proliferating cells as judged by 
staining for Ki67, which is nuclear in cycling cells (Fig. 3 D, 
top; arrows). These data are suggestive of a perturbation in 
the mechanism that normally restricts dividing cells to the 
basal layer. In contrast, we observed no obvious change in 
apoptosis, as indicated by either histology or antibody staining 
against the activated form of caspase 3. The caspase 3–  positive 
cells (Fig. 3 D, bottom; arrows) in catagen-phase hair follicles 
undergoing cyclic apoptosis provided a nice internal control 
for these stainings.
Additional changes underlying the 
hyperproliferative defects in AP-2𝗂 
conditionally null mice
Because the alterations we observed in differentiation patterns 
are classical features of hyperproliferation, they could 
represent a refl   ection of an abnormality in the proliferative 
  machinery of the epidermis. Alternatively, if these changes 
were a primary consequence of a loss of AP-2α, it is possible 
that the alterations in differentiation could perturb the   epider-
mal barrier, which is a process known to result in   indirect AP-2α: BALANCING GROWTH AND DIFFERENTIATION • WANG ET AL. 413
Figure 4.  Intact epidermal barrier but elevated EGFR expression and signaling in hyperproliferative AP-2𝗂–null skin. (A) Barrier function assay. Newborn 
litters were placed in blue dye to test for the presence of an intact epidermal barrier. Note tail cut for genotyping and umbilicus show areas of blue staining, 
indicating dye penetration in areas where there is loss of barrier. (B) Semiquantitative RT-PCR of neonatal epidermal mRNAs. Epidermis was separated from 
the rest of the skin (including hair follicles) by enzymatic treatment with dispase. After mRNA isolation, semiquantitative RT-PCR was conducted using primer 
sets speciﬁ  c for EGFR (test) and GAPDH (control) mRNAs. All bands were of the expected size and were generated only in the presence of reverse tran-
scriptase (RT). (C) Anti-EGFR and antiphospho-EGFR immunoblot analyses of epidermal proteins isolated from neonatal mice in which the cKO epidermis 
is hyperproliferative. Anti-tubulin is used as a control. (D) EGFR immunoﬂ  uorescence of sections of hyperproliferative cKO skins and WT counterparts from 
P0 mice. Inset shows a high magniﬁ  cation confocal image of the colocalization of phospho-EGFR and E-cadherin at the membrane. Arrows denote supra-
basal phospho-EGFR staining. (E) Same as in D, but on adult thoracic skins. Epi, epidermis; de, dermis; hf, hair follicle. Dotted lines denote dermo–
  epidermal borders. Solid white lines denote skin surface. (F) Same as in C, but on adult epidermis. Normalizations are to anti-tubulin. Bars, 20 μm.
 hyperproliferation (Segre et al., 1999). To begin to understand 
the   underlying basis for the phenotype, we fi  rst performed a dye 
penetration assay on newborn WT and AP-2α–null pups (Segre 
et al., 1999). With the exception of the tail and umbilicus, which 
were severed in both WT and null pups, toluidine blue dye did 
not penetrate the skin (Fig. 4 A). When coupled with the mosaic 
hyperproliferative defects seen in the AP-2α–null skin, these re-
sults indicated that there must be other molecular events that are 
dependent on AP-2α and that render the epidermis susceptible to 
an imbalance in proliferation and differentiation.
Members of the EGF and insulin growth factor (IGF) fam-
ilies are particularly important in regulating proliferation in the 
epidermis (for review see Fuchs and Raghavan, 2002). Of these, 
TGFα and EGFR genes were particularly interesting in that 
they both harbor AP-2–binding sites in their promoters. 
  Additionally, constitutive expression of TGFα in transgenic 
mice results in a transient epidermal hyperproliferation that 
wanes in the adult and can reemerge after wounding and/or me-
chanical stress (Vassar and Fuchs, 1991; Dominey et al., 1993), 
whereas overexpression of constitutively active members of the 
receptor family can lead to papilloma undulations throughout 
the skin (Xie et al., 1999). Finally, EGF injection in sheep skin 
results in concomitant hair loss and epidermal thickening 
(Moore et al., 1985), whereas EGFR down-regulation has been 
associated with hair follicle formation (Atit et al., 2003). Col-
lectively, although all prior gene studies have argued for a posi-
tive rather than a negative effect of AP-2α on EGF signaling 
pathway genes (Johnson, 1996; Wang et al., 1997; Vernimmen 
et al., 2003; Begon et al., 2005), the signifi  cant physiological 
parallels prompted us to focus on the status of genes involved in 
EGF signaling in our cKO animals.
We fi rst performed semiquantitative RT-PCR on mRNAs 
from purifi  ed hyperproliferative AP-2α neonatal cKO and WT 
epidermis. By this criteria, EGFR mRNA levels were signifi  cantly 
elevated (Fig. 4 B). Immunoblot analysis showed that the increase 
in EGFR mRNA expression was refl  ected at the protein level 
(Fig. 4 C). Immunofl  uorescence microscopy furtherrevealed 
sustained expression of EGFR in the suprabasal layers of AP-2α–
null epidermis (Fig. 4 D). This difference was   evident by P0, 
  making it an early consequence of the AP-2α   targeting event. 
Furthermore, the increase in epidermal thickening was associated 
with the phosphorylated (i.e., activated) form of the receptor.JCB • VOLUME 172 • NUMBER 3 • 2006  414
Figure 5.  EGFR levels are elevated in nonproliferative regions of adult AP-2𝗂–null skin, but EGFR signaling is silent unless externally stimulated. (A) H&E 
and immunoﬂ  uorescence of sections of nonproliferative cKO skins and WT counterparts from P6 mice. Antibodies are against EGFR, phosphorylated (ac-
tive) EGFR, and K6. Note elevated EGFR but not phospho-EGFR or K6 in P6 cKO skin. (B) H&E and anti-EGFR/antiphospho-EGFR immunoﬂ  uorescence of 
sections of nonproliferative cKO and WT adult back skins. (C) Immunoblot analyses of epidermal proteins isolated from adult back skin from WT and AP-2α 
conditionally null mice. Blots were probed with antibodies against the proteins indicated at right. Note elevated EGFR but not phospho-EGFR, which is nor-
mally weak in thin adult skin. (D) mRNAs were isolated from WT and cKO adult back skin or neonatal epidermis and subjected to real-time PCR using a 
primer set speciﬁ  c for TGFα mRNA. Controls shown are for the reaction involving the primer set alone in the absence of added mRNA. Error bars represent 
SD. (E) Back skins of adult AP-2α–null and control littermates were treated with TPA, a procedure known to elevate the expression of EGFR ligands (Kiguchi 
et al., 1998). After treatment, skins were processed for H&E and EGFR/phospho-EGFR immunoﬂ  uorescence microscopy. No papillomas were observed 
even after 4 mo of treatment. Epidermal thickening was accompanied by EGFR activation, both of which were more robust in the TPA-treated cKO animals. 
Epi, epidermis; de, dermis; hf, hair follicle. Dotted lines denote dermo–epidermal borders. Bars, 20 μm.
The epidermis of adult mice is typically thin, and its 
proliferative activity is low. Correspondingly, it was not sur-
prising to see a single layer of anti-EGFR labeling with very 
little phospho-EGFR labeling in WT adult skin (Fig. 4 E). 
In contrast, the lesional regions of AP-2α–null epidermis dis-
played elevated levels of not only total but also autophos-
phorylated EGFR. The AP-2α null–associated up-regulation 
in total EGFR was confirmed by immunoblot analyses, as 
was the elevated levels of activated EGFR in lesional 
  regions of the cKO mice (Fig. 4 F).
EGFR levels are elevated in adult AP-2𝗂–null 
back skin, which is not hyperproliferative
A priori, the observed elevation in EGFR and/or signaling could 
be caused either directly by the loss of AP-2α or indirectly by 
the enhanced proliferation that occurs concomitantly with the 
absence of AP-2α. To distinguish between these possibilities, 
we fi  rst examined P6 AP-2α–null and WT back skin (Fig. 5 A). 
Despite the similar morphologies and thickness of WT and 
AP-2α–null epidermis at this age (Fig. 2 A), EGFR was still el-
evated in the absence of AP-2α. Interestingly, however, anti-
bodies against the phosphorylated form of EGFR showed no 
difference between WT and cKO skin, suggesting that the 
EGFR was not active. Further consistent with the lack of EGFR 
signaling and hyperproliferation in these regions was the lack of 
anti-K6 staining in the epidermis.
Similarly, in adult back skin, the AP-2α–null epidermis 
appeared largely normal (Fig. 5 B). By immunofl  uorescence 
analysis, however, the EGFR levels were clearly elevated. AP-2α: BALANCING GROWTH AND DIFFERENTIATION • WANG ET AL. 415
Figure 6. Regulation  of  EGFR gene expres-
sion by AP-2𝗂. (A) Primary WT and AP-2α–null 
keratinocytes were cultured in rich medium 
(15% serum, growth factors, high density, and 
with feeder layer). When indicated, 1.5 mM 
Ca
2+ was added to induce terminal differentia-
tion. Protein lysates and RNA were prepared 
after removal of the feeder cells by treatment 
with 0.1 mM EDTA. Immunoblots of keratino-
cyte proteins probed for AP-2α and AP-2γ are 
shown, along with real-time PCR of keratino-
cyte mRNAs tested for K1 and involucrin 
  expression. Real-time data are normalized to 
0.05 mM calcium (= 1). (B) Immunoblot analy-
sis and real-time PCR of keratinocyte protein 
and mRNAs tested for EGFR expression. 
(C) Chromatin  immunoprecipitation  (ChIP). 
(top) Within 1.2 kb of sequence 5′ from the 
putative transcriptional initiation site of the 
mouse EGFR gene are four consensus AP-2–
binding sites (ovals), two of which are con-
served (in red). ChIP, WT, and KO keratinocytes 
were either treated or not treated with formal-
dehyde to transiently cross-link proteins to 
chromatin. Both cross-linked and noncross-
linked chromatin was isolated and sheared to 
 400-bp fragments. Immunoprecipitations 
were then performed using anti-AP2α or no 
antibody or control IgG antisera. PCR analyses 
on the immunoprecipitated fragments were 
performed using primers encompassing the 
putative AP-2–binding sites located within the EGFR promoter (marked on the diagram). Note that only the combination of formaldehyde cross-linking and 
the application of anti–AP-2α antibody speciﬁ  cally immunoprecipitated AP-2α site-containing EGFR promoter sequences in WT and not in KO keratinocytes. 
(D) Luciferase assays of EGFR promoter activity in primary WT or KO mouse keratinocytes ± infection with the AP-2α–expressing   retroviral vector (see Sepa-
ration of epidermis…transfections). 1.2 kb of sequence 5′ from the transcription initiation site of the EGFR promoter (see C) was used to drive ﬁ  reﬂ  y lucifer-
ase expression (pEGFRpr-Luc). pMutEGFRpr-luc was engineered by introducing point mutations in the three AP-2 sites within the parent vector. Fold 
increases represent EGFRpr ﬁ  reﬂ  y luciferase activity divided by the basal level of p-Luc ﬁ  reﬂ  y luciferase activity, with cytomegalo virus–Renilla luciferase 
  activity as the standardized internal control for transfection efﬁ  ciency. The graph represents three independent experiments   performed in duplicate. Error 
bars represent SD for these experiments. Asterisk denotes a signiﬁ  cant difference from WT cells (P < 0.001) by t test.
In contrast to hyperproliferative AP-2α cKO thoracic skin, the 
levels of tyrosine-phosphorylated EGFR remained low. This 
was confi  rmed by immunoblot analyses (Fig. 5 C).
Based upon these data, two important fi  ndings emerged. 
First, AP-2α loss resulted in increased EGFR expression. 
  Second, the hyperproliferative phenotype correlated with the 
activation of these EGFR tyrosine kinases, a process which is 
typically dependent on ligand. TGFα is both a ligand for EGFR 
and a potent growth factor of epidermal keratinocytes in vitro 
(Barrandon and Green, 1987). In nonlesional adult back skin, 
TGFα mRNAs were extremely low in both WT and cKO mice 
(Fig. 5 D). In contrast, in neonatal (P2) epidermis, where EGFR 
activity and proliferation were detected in both WT and cKO 
mice, TGFα mRNAs were readily detectable (Fig. 5 D). The 
levels were slightly higher in cKO relative to WT P2 epidermis, 
and this and/or other EGF signaling molecules could enhance 
the effects of elevated EGFR in neonatal cKO mice. Altogether, 
the patterns of TGFα, EGFR, and EGFR activation were consis-
tent with the phenotypic effects observed.
To further explore these parallels, we took advantage of the 
previous observation that topical application of 12-O-tetradec-
anoylphorbol-13-acetate (TPA) causes elevation of TGFα, lead-
ing to activation of EGFR in adult skin (Kiguchi et al., 1998). If, 
as we surmise, the epidermal hyperproliferation seen in lesional 
AP-2α–null skin is at least in part caused by regional activation 
of elevated EGFRs, nonlesional AP-2α–null back skin might be 
expected to show elevated thickening upon TPA treatment.
At the doses of TPA administered in this study, TPA treat-
ment had only a modest effect on the back skin of control adult 
mice. In contrast, these TPA treatments caused hyperthickening 
of the AP-2α–null back skin accompanied by activation of EG-
FRs (Fig. 5 E). These morphological aberrations were accom-
panied by an increase in proliferation and biochemical alterations 
that are typical of a hyperproliferative state (not depicted). Even 
after 4 mo of treatment, however, no signs of tumor formation 
or progression were observed, indicating that AP-2α loss alone 
was not suffi  cient to cause skin tumorigenesis.
EGFR is a direct target of AP-2𝗂
To further probe the underlying mechanisms responsible for the 
up-regulation of EGFR in the absence of AP-2α, we cultured 
primary keratinocytes from neonatal WT and cKO mouse skins. 
To evaluate the data, it was fi  rst essential to examine the 
 expression  of  AP-2α and AP-2γ in vitro to see whether the pref-
erential suprabasal expression of AP-2α was recapitulated in 
culture, as we had observed in epidermis (Fig. 1). To examine 
this, we induced terminal differentiation by elevating the cal-
cium levels in the medium and then performed immunoblot 
analyses on protein extracts from low- and high-calcium 
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shift, the expression of the spinous layer markers K1 and invo-
lucrin were elevated, although appreciable involucrin mRNA 
was present even in the low-calcium state. Within the same time 
frame, AP-2α was largely unaffected by calcium treatment rela-
tive to internal protein loading standards. In contrast, AP-2γ 
was markedly decreased upon calcium-induced differentiation. 
Moreover, the levels of AP-2γ were not appreciably changed in 
the AP-2α–null cells (Fig. 6 A). Together, these data were con-
sistent with our prior in vivo data presented in Fig. 1.
Next, we conducted immunoblot studies in which we could 
examine EGFR levels under conditions where we could more rig-
orously control for microenvironment and cell numbers. As shown 
in Fig. 6 B, EGFR levels were elevated in the AP-2α–null kerati-
nocytes relative to their WT counterpart. Under enriched culture 
conditions, both cell populations displayed phosphorylated EGFR 
(not depicted). These changesin AP-2α–null keratinocytes were 
also refl  ected at the mRNA level (Fig. 6 B). Real-time PCR 
showed a fourfold increase in EGFR mRNAs in KO versus WT 
cells. TGFα mRNA levels were only modestly elevated in the 
AP-2α–null state (not depicted).
If AP-2 acts to repress EGFR gene transcription, it should 
bind to the endogenous EGFR promoter. Previous studies 
have shown that recombinant AP-2α can bind to an AP-2 
consensus motif in the human EGFR promoter (Johnson, 1996; 
Oyama et al., 2002). In the mouse EGFR promoter, multiple 
AP-2 consensus binding sites are situated within a kilobase 
  upstream from the transcription initiation site (Fig. 6 C, ovals). 
Two of these sites are conserved across mammalian species 
(Fig. 6 C, ovals highlighted in red). To evaluate whether 
 en dogenous  AP-2α binds directly to one or more of these sites 
in epidermal cells, we conducted chromatin immunoprecipita-
tion (ChIP) assays using the monospecifi  c anti–AP-2α antibody. 
Anti–AP-2α antibodies specifi  cally  immunoprecipitated 
  chromatin–protein complexes that contained an  500-bp DNA 
fragment encompassing the conserved putative AP-2α–binding 
sites (Fig. 6 C). In contrast, ChIP analysis of WT skin did not 
display PCR bands with primers corresponding to either the 
EGFR promoter or downstream regions that did not contain 
AP-2–binding motifs (not depicted). These data provided the 
fi  rst ChIP data illustrating the binding of AP-2α to an endoge-
nous gene that contains AP-2 consensus binding motifs.
To test whether EGFR gene transcription is affected by the 
loss of AP-2α, we transfected Ca
2+ grown keratinocytes with a 
luciferase reporter gene driven by a 1.1-kb EGFR promoter 
fragment harboring the AP-2α–binding sites. By 48 h, luciferase 
activity was markedly elevated in AP-2α–null versus WT cells 
(Fig. 6 D). Point mutations in the AP-2α motifs raised EGFR 
promoter activity levels in WT but did not affect AP-2α–null 
cells. Finally, we infected WT and KO keratinocytes with a ret-
roviral AP-2α expression vector and repeated the EGFR reporter 
assay. Exogenous expression of AP-2α resulted in a potent re-
pression of luciferase activity driven by the WT EGFR promoter 
but not its mutant counterpart (Fig. 6 D). These data underscore 
the AP-2–specifi  c nature of the manipulations and the repressive 
effects on EGFR transcription. These fi  ndings further suggest 
that AP-2α functions in suppressing EGFR gene expression as 
epidermal cells commit to terminally differentiate.
Abnormal EGFR signaling circuits 
in AP-2𝗂–null skin
To evaluate how downstream signaling events may be affected 
when EGFR levels are elevated, we fi  rst examined the prolifera-
tive potential of primary AP-2α–null and WT epidermal kerati-
nocytes. Both populations grew equally well when plated at 
high density on a fi  broblast feeder layer and in rich growth 
  media (unpublished data). However, when subjected to more 
stringent conditions such as sparse plating with no feeder layer 
for long term growth (>5 d) or low serum/growth factor– 
supplemented medium, only KO keratinocyte cultures grew 
well (representative examples in Fig. 7 A). Moreover, the growth 
advantage of the KO keratinocytes was largely eliminated by 
the addition of AG1478, an EGFR-specifi  c protein kinase in-
hibitor, to the culture medium, suggesting that increased EGFR 
signaling might be responsible for the enhanced proliferative 
potential observed in KO keratinocytes.
EGFR stimulation typically leads to downstream activa-
tion of the MAPK family members Erk1/2, but it can also 
lead to activation of Akt kinases. Both are required for epi-
dermal growth and differentiation (Schlessinger, 2000; Sibilia 
et al., 2000). To determine whether the loss of AP-2α and 
  elevated EGFR signaling results in an elevated activation of 
MAPK (Erk1/2) and/or Akt pathways, we stimulated 24-h 
  serum-starved cells with EGF. Within a minute after stimula-
tion, the two populations activated Erk1/2 with similar 
kinetics (Fig. 7 B). Relative to total Erk1/2, the phosphory-
lated (i.e., activated) Erk1/2 signals were always higher in the 
KO keratinocytes. This was visualized over a range of EGF 
concentrations (Fig. 7 C). Although AP-2–null keratinocytes 
activated more Erk1/2 in response to EGFR ligands, the most 
signifi   cant difference observed was in EGF-mediated Akt 
  activation. Again, the fi  rst signs of activation appeared within 
a minute after exposure to EGF. However, relative to equiva-
lent levels of total Akt, phosphorylated (i.e., activated) Akt 
was nearly an order of magnitude higher in KO cells across a 
range of EGF concentrations.
Remarkably, as little as 0.5 ng/ml EGF was suffi  cient to 
elicit these differences in Erk1/2 and Akt activation. Curiously, 
the differential effects on Akt appeared to be specifi  c for EGFR 
signaling, whereas the differential activation of Erk1/2 was also 
seen with IGF-1, another potent stimulator of keratinocyte 
growth and survival (Fig. 7 D). The effects were obliterated by 
treatment with the PI3K-specifi  c inhibitor LY294002,  indicating 
that Akt activation in EGF-treated keratinocytes was mediated 
through PI3K activation (Fig. 7 E).
To test the physiological relevance of these fi  ndings, we 
examined the status of activated Akt in our mice. In nonlesional 
regions of AP-2α–null skin where EGFRs were elevated but not 
activated, phospho-Akt levels remained low and comparable 
with WT skin (Fig. 7 F and not depicted). However, in either 
TPA-treated or thoracic cKO skin, activated Akt was markedly 
elevated. Even in WT skin, TPA treatment resulted in mildly 
up-regulated levels of activated Akt, which is consistent with the 
modest epidermal thickening we noted previously (Fig. 5 D). 
Based upon these criteria, the mechanisms uncovered in our in 
vitro analyses appeared to be operative in vivo.AP-2α: BALANCING GROWTH AND DIFFERENTIATION • WANG ET AL. 417
Discussion
The AP-2𝗂 and EGFR connection 
and its relevance to growth control 
in the epidermis
AP-2–binding sites have been found in a myriad of genes 
  differentially expressed in both basal and suprabasal compart-
ments of mammalian epidermis (Hilger-Eversheim et al., 2000; 
for review see Fuchs and Raghavan, 2002). However, to date, 
their functional signifi  cance has remained elusive. In this study, 
we have shown that AP-2α plays a role in the switch between 
epidermal cell proliferation and differentiation, and we have 
provided the fi  rst experimental evidence to integrate this tran-
scription factor into a key signaling pathway in the skin. The 
fi  nding is especially important given that some studies have 
highlighted AP-2α as a tumor suppressor (Ropponen et al., 
2001; Pellikainen et al., 2004; Friedrichs et al., 2005), whereas 
others have suggested a growth-promoting effect of the protein 
(Bosher et al., 1996; Vernimmen et al., 2003). Our study clar-
ifi  es how AP-2α governs epidermal proliferation and provides 
important new insights into why inverse correlations are often 
found between AP-2α and EGFR family members in human 
epithelial cancers.
Our studies place AP-2α in the EGFR signal transduction 
cascade. Using in vivo and in vitro approaches, we found that 
EGFR gene expression was elevated upon genetic ablation of 
AP-2α or by mutation of the AP-2–binding sites in the EGFR 
promoter. Correspondingly, EGFR gene expression was down-
regulated when AP-2α was added back to the KO cells through 
retroviral transgene expression. Although AP-2α is likely to 
have many other target genes in epidermis, several of the pheno-
typic abnormalities in the AP-2α conditionally null mice can be 
explained by EGFR misregulation.
EGFRs have long been known to play an important role in 
regulating the development of the epidermis and its appendages 
(Luetteke et al., 1994; Miettinen et al., 1995; Sibilia and  Wagner, 
1995; Threadgill et al., 1995). In mammals and birds, over-
expression or injection of EGF can arrest epidermal appendage 
development and promote epidermal thickening, and,  conversely, 
activation of EGFRs is typically diminished in areas of follicle 
formation (Moore et al., 1985; Kashiwagi et al., 1997; Atit et al., 
2003). Postnatally, EGFRs are predominantly expressed in the 
basal epidermal layer and down-regulated as cells commit to 
terminally differentiate (King et al., 1990).
Once activated, EGFR has the ability to activate Ras–
MAPK signaling, which is often linked to proliferation, as well 
as PI3K–Akt signaling, which is more typically associated with 
cell survival (Rodeck et al., 1997; Schlessinger, 2000). Relevant 
to the data presented here, tumorigenesis can arise from super-
activated Ras–MAPK signaling in transgenic mouse skin but 
only in conjunction with EGFR signaling to activate PI3–Akt 
(Sibilia et al., 2000). A key feature of EGFR signaling is that its 
activation is dependent on ligand stimulation. Made and se-
creted by salivary glands, EGF can enter the bloodstream and 
reach epidermal tissue, whereas TGFα is the major autocrine 
growth factor of the epidermis. TGFα is down-regulated post-
natally but can be up-regulated upon injury or TPA treatment 
(Kiguchi et al., 1998). That postnatal skin is limiting for EGFR 
ligands is graphically illustrated by the papilloma-like undula-
tions that develop in skin of mice engineered to overexpress an 
EGFR relative (ErbB2) that lacks the requirement for ligand 
stimulation (Xie et al., 1999; Kiguchi et al., 2000).
When placed in the context of these prior studies, we can ac-
count for many of the features of the seemingly complex phenotype 
of our AP-2α cKO mice. The hyperproliferation that occurs in cKO 
newborn epidermis despite elevated EGFR levels suggests that the 
ligand pool for these receptors must be quite large at this age. The 
levels appear to be saturating for WT but not cKO EGFR levels, and 
this is refl  ected by the observed enhancement of phosphorylation 
and activation of the EGFRs in newborn cKO skin. Soon after birth, 
hyperproliferation and phosphorylation of   EGFRs returns to nor-
mal in cKO despite sustained elevated EGFR levels in cKO skin. 
After embryogenesis, the ligand pool is known to be attenuated 
along with other growth-promoting signals, and our results indicate 
that these pool levels have dipped below saturation even for WT 
EGFRs. Finally, the markedly hyperproliferative epidermis and 
phosphorylation of EGFRs in lesional but not nonlesional regions 
of adult cKO thoracic and ear skin and TPA-treated cKO back skin 
is refl  ective of the elevated ligand pools that are known to arise 
upon mechanical irritation and TPA treatment. Additionally, when 
animals lick their wounds, the EGF-rich saliva could further con-
tribute to the robust proliferative response in the ventral chin area.
An additional point worthy of mention is that the AP-2α–
null papilloma-like undulations were not as severe as the spon-
taneous skin tumors that arise from chemical or transgenic 
mutations in epidermally expressed Ha-Ras. We surmise that 
the underlying reason for this may be rooted in the normal feed-
back regulatory loops that are operative in dampening the dele-
terious effects of overly active EGFR signaling. Indeed, for 
sustained epidermal hyperproliferation and tumorigenesis to 
occur on a background of Ha-Ras mutations, sustained EGFR 
signaling must still be permitted to activate and sustain elevated 
PI3K–Akt signaling (Sibilia et al., 2000).
Our data shed additional insight onto this signaling cir-
cuitry by demonstrating that the EGFR response to Akt activa-
tion is different than that of IGF receptor in epidermal cells and 
that in situations in which EGFR signaling is hyperactive, Akt 
activation can be very high and suprabasal proliferation can 
  occur. Although Akt activation is typically associated with cell 
survival, several examples that link PI3K–Akt activation to pro-
liferation may be relevant to the fi  ndings we report. Sustained 
PI3K–Akt activation also occurs in liver tumors, where it post-
translationally silences the C/EBPα transcriptional repressor 
that controls hepatocyte proliferation (Wang et al., 2004). 
 Intriguingly,  C/EBPα has also been implicated in epidermal dif-
ferentiation and is repressed in some skin cancers (Shim et al., 
2005). Although beyond the scope of this study, such a mecha-
nism could explain why AP-2α null–mediated hyperactivation 
of the EGFR–PI3K–Akt pathway leads to an increase in prolif-
eration and epidermal thickening in vivo.
AP-2 and transcriptional regulation in skin
After 15 yr since the original implication of AP-2 in transcrip-
tional regulation in the epidermis (Leask et al., 1990; Snape JCB • VOLUME 172 • NUMBER 3 • 2006  418
Figure 7.  In vitro and in vivo superactivation of the PI3K–Akt pathway in an EGF-dependent and AP-2𝗂 null–dependent fashion. (A) Primary WT and 
KO keratinocytes were cultured ± the EGFR-speciﬁ  c protein kinase inhibitor AG1478 without the addition of ﬁ  broblast feeder cells after the original plat-
ing. Growth curves represents three independent experiments performed in duplicate (see Separation of epidermis...transfections). Error bars represent 
SD for these experiments. (B) Keratinocytes were serum-starved for 24 h and at t = 0, 50 ng/ml EGF was added. At the times indicated, cell extracts 
were prepared, proteins were resolved by SDS-PAGE, and immunoblot analyses were conducted with the antibodies indicated at right. The antibodies 
against the active forms of Erk1/2 and Akt (p-Erk and p-Akt, respectively) are phosphospeciﬁ  c antibodies and do not recognize the inactive states of the 
kinases. β-tubulin antibodies are used as a loading control, along with ponseau red staining of the blots (not depicted). Note EGF-dependent superactiva-
tion of Akt and Erk1/2 in AP-2α–null keratinocytes. (C) Same experiment as in B, except 10× increments of EGF concentrations (0–50 ng/ml) were used, 
and extracts were harvested at t = 2 min. (D) Same experiment as in B, but insulin growth factor 1 (IGF1) was added at 50 ng/ml. Note that in contrast 
to EGF, IGF1 did not generate enhanced activated Akt in KO relative to WT cells. (E) Same experiment as in B, but the PI3K-speciﬁ  c inhibitor LY294002 
was added at 20 μM. Note that the activation of Akt, but not Erk1/2, is dependent on PI3K activation. (F) Antiphospho-Akt staining of frozen 
sections (8 μm) from (top) lesional KO and WT thoracic skins and (bottom) TPA-treated KO and WT back skins. Note the superactivation of Akt in KO skin 
regions that are lesional and that correlate with elevated EGFR ligand expression. De, dermis; epi, epidermis; hf, hair follicle. Dotted lines denote 
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et al., 1991), the functional importance of these proteins in epi-
dermis is now emerging. Recent knockdown experiments 
  underscore a role for Xenopus laevis AP-2α in embryonic skin 
development (Luo et al., 2002), and our studies now reveal an 
essential role for mammalian AP-2α in orchestrating the bal-
ance between epidermal proliferation and differentiation. This 
process can be largely explained by AP-2α’s repressive effects 
on EGFR gene transcription, but given the repertoire of epider-
mally expressed genes with AP-2–binding sites, there are likely 
to be many additional key genes controlled by AP-2α. Why 
have these other target genes not surfaced in our analyses?
The answer seems, at least in part, to reside in functional 
redundancy among AP-2 family members, four of which are 
  expressed in the epidermis. This is substantiated by the fact that 
both in vivo and in vitro, the consequences of AP-2α ablation ap-
peared to be more dramatic in the differentiating cells where 
AP-2γ expression is down-regulated. Additionally, AP-2α ap-
pears to be more highly expressed in those basal cells that are not 
actively cycling, leading us to speculate that AP-2’s role may be 
most critical at the juncture between proliferation and differentia-
tion in the epidermis. Evaluating the degree of AP-2 functional 
redundancy in the epidermis must await functional studies on the 
other members of the AP-2 family that are   expressed in skin.
Cell type and differentiation-specifi  c cofactors are likely 
to further impact the complexities of when and how AP-2 pro-
teins act in the epidermis. Studies in other systems have already 
indicated that interactive partners for AP-2 proteins can infl  u-
ence whether AP-2 proteins act as transcriptional repressors or 
activators (Pfi  sterer et al., 2002). Differences in AP-2 recogni-
tion motifs are also likely to infl  uence target gene specifi  city, 
and the differential expression of AP-2 family members and 
possibly putative AP-2 cofactors could further magnify differ-
ences in the spatial and temporal behavior of putative AP-2 tar-
get genes within a tissue. Such differences are also likely to 
contribute to our understanding of why the loss of AP-2β results 
in massive apoptosis in the kidney (Hilger-Eversheim et al., 
2000) and why the loss of AP-2α in neural crest impaired cra-
niofacial development and pigmentation (Brewer et al., 2004). 
These issues are also likely to underlie the seemingly opposing 
fi  ndings that the addition of recombinant AP-2α to a nuclear 
extract from a human squamous cell carcinoma line in vitro led 
to an increase in EGFR transcription (Johnson, 1996), whereas 
AP-2α in mouse epidermis and in cultured epidermal keratino-
cytes had an inhibitory effect on EGFR promoter activity (our 
study). The fi  nding that AP-2 proteins positively regulate cell 
proliferation in some cells and inhibit growth in others may help 
in the future to explain the seemingly disparate results obtained 
concerning the roles for AP-2 family members in human can-
cers (Bosher et al., 1996; Ropponen et al., 2001; Vernimmen 
et al., 2003; Pellikainen et al., 2004; Friedrichs et al., 2005).
Materials and methods
Generation of cKO mice
AP-2α ﬂ  oxed mice (AP-2α
lox) and K14-Cre transgenic mice were generated 
as described previously (Vasioukhin et al., 1999; Brewer et al., 2004). 
Genotyping was conducted by PCR of tail skin DNAs.
Histology, immunoﬂ  uorescence, and in situ hybridization
For light or ﬂ  uorescence microscopy, tissues were embedded in optimal 
cutting temperature compound and frozen on dry ice. For semi-thin sec-
tions and transmission EM, tissues were ﬁ  xed and processed as previously 
described (Vasioukhin et al., 2001). For indirect immunoﬂ  uorescence, 
10-μm sections were permeabilized with 0.1% Triton X-100 and washed. 
For mouse monoclonal antibodies, we used the MOM kit (Vector Labora-
tories); for antibodies from other species, we used 2.5% normal donkey 
  serum, 2.5% normal goat serum, 1% BSA, 2% gelatin, 0.1% Triton X-100 
as block, and antibody diluent.
Primary antibodies used are as follows: (1) mouse: AP-2α (1:5; T. 
Williams) and phospho-EGFR (1:200; Upstate Biotechnology); (2) rabbit: 
K6 (1:200; Fuchs laboratory), K1 (1:250; Fuchs laboratory), Ki67 
(1:1,000; Novocastra laboratories), active caspase 3 (1:500; R&D 
  Systems), K17 (1:1,000; a gift from P. Coulombe, The Johns Hopkins 
  University School of Medicine, Baltimore, MD), EGFR (1:100; Upstate 
Biotechnology), and phospho-Akt (1:250, Cell Signaling); (3) guinea pig: 
K5 (1:200; Fuchs laboratory); (4) rat: BrdU (1:150, AbCam) and β4 inte-
grin (1:250, BD Biosciences). For phospho-EGFR staining, sections were 
ﬁ  xed in cold 100% methanol, primary antibody incubations were per-
formed as above, and the signal was ampliﬁ  ed using the ABC kit (Vector 
Laboratories) and visualized using the tyramide signal ampliﬁ  cation Plus 
Fluorescence detection kit (PerkinElmer). In situ hybridizations of 
K5 transcripts were performed as described previously (Byrne et al., 
1994). Probe synthesis was performed according to the manufacturer’s 
instructions (Roche).
Image acquisition and manipulation
The histology, immunoﬂ  uorescent, and in situ hybridization images were 
taken by a mot plus microscope (Axioskop 2; Carl Zeiss MicroImaging, 
Inc.). The objectives used were 20× NA 0.5 plan Neoﬂ  uar ∞/0.17 and 
40× NA 1.3 oil plan Neoﬂ  uar ∞/0.17 (Carl Zeiss MicroImaging, Inc.). 
The images were taken at room temperature in antifade as an imaging 
  medium for immunoﬂ  uorescent images and 80% glycerol for hematoxylin 
and eosin (H&E) images. The ﬂ   uorochromes used were FITC, Texas 
red/rhodamine red X, and DAPI. A slider camera (SPOT RT; Diagnostic 
Instruments) and MetaMorph 6 (Molecular Devices) software were used 
to   acquire the pictures. Adobe Photoshop 6.0 software was used for con-
trast and brightness adjustment. The immunoblot and PCR gel images were 
  acquired with an Alphaimager (Innotech), and Quantity One software 
(Bio-Rad Laboratories) was used for contrast and brightness adjustment.
Separation of epidermis, keratinocyte isolation, culture, and transfections
Enzymatic separation of epidermis from skins and primary newborn mouse 
epidermal cell cultures were performed as described previously (Blanpain 
et al., 2004). To induce keratinocyte differentiation in culture, the calcium 
concentration of the media was raised from 0.05 to 1.5 mM for 24 h, after 
which protein and RNA were extracted.
For growth comparisons, 2.5 × 10
4 of freshly isolated cells were 
plated with feeder layers in 24-well dishes. For stringent growth conditions, 
serum was adjusted to 2%, and/or growth factor supplements and the 
  addition of ﬁ  broblast feeder cells were omitted. For growth comparisons 
with the presence of AG1478, 200 nM of the inhibitor (Sigma-Aldrich) 
was added to the serum daily after plating. Keratinocyte numbers were 
  determined with a coulter counter.
Nucleotides −1,180–29 (transcription initiation site = 0) of the 
mouse  EGFR promoter were cloned upstream of the ﬁ  reﬂ  y  luciferase 
gene in the pGL2 basic plasmid (Promega). Cells were transferred into 
12-well dishes and grown to 30–40% conﬂ  uency before Fugene 6 (Roche) 
  reagent-assisted transfections of 2 ng cytomegalo virus–Renilla luciferase 
DNA (control) and 100 ng of either WT or mutant EGFR promoter ﬁ  reﬂ  y 
  luciferase constructs (pEGFRpr-Luc or pMut-EGFRpr-Luc) or empty vector 
(p-Luc; Promega). 48 h after transfection, luciferase assays were performed 
as described previously (Sinha et al., 2000; Kaufman et al., 2002). Trans-
fection efﬁ  ciency was 2–3%. A retroviral vector containing the full-length 
mouse AP-2α cDNA was engineered and infected for AP-2α rescue studies 
(70% efﬁ  ciency).
TPA treatment
Mice were anesthetized, and their backs were shaved. Each mouse   received 
2.5 μg TPA (dissolved in acetone) on the right half of the back twice per 
week for 4 mo. As a control, the left half was treated with acetone.
ChIP
In vivo ChIP was performed as described previously (Jamora et al., 2003). 
The presence of AP-2α sites was conﬁ  rmed by rVista analysis of 5′   upstream JCB • VOLUME 172 • NUMBER 3 • 2006  420
sequences as deﬁ  ned by the ECR Browser and Ensemble software (Euro-
pean Bioinformatics Institute and Sanger Institute). AP-2 sites were chosen 
for ChIP analysis based on the conservation and alignment between mouse 
and at least one other species, including human, canine, and rat, and clus-
tering of sites when applicable. As a control, PCR was also performed 
  using primers that recognize other sites within the same promoter or down-
stream portions of the same gene to demonstrate the speciﬁ   city of the 
pull-down.
AP-2𝗂, AP-2𝗄, EGFR, MAPK (Erk1/2), and Akt activity measurements
SDS-PAGE and immunoblot analyses were used to identify the AP-2α, 
AP-2γ, EGFR, MAPK (Erk1/2), and Akt proteins. AP-2α and AP-2γ proteins 
were identiﬁ   ed with monoclonal antibodies against AP-2α and AP-2γ 
(Santa Cruz Biotechnology, Inc.), respectively. The active (i.e., phosphory-
lated) forms of the EGFR, MAPK, and Akt proteins were identiﬁ  ed with phos-
phospeciﬁ   c antibodies against EGFR (Tyr1173; Upstate Biotechnology), 
MAPK (Thr183 and Tyr185 in Erk2; Sigma-Aldrich), and Akt (Ser473; Cell 
Signaling), respectively. The total levels of these proteins were identiﬁ  ed 
with panel antibodies against EGFR (Upstate Biotechnology), MAPK (Cell 
Signaling), and Akt (Cell Signaling), respectively.
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